FDA Grants Fast Track Designation to MorphoSys AG’s Promising Endometrial Cancer Treatment
CyGenica Receives Orphan Drug Designation for Glioblastoma Multiforme (GBM) Treatment
Healx Secures FDA Orphan Drug Designation for AI-Discovered NF1 Treatment – HLX-1502 Unveiled!
INOVIO’s INO-3107 Granted FDA Breakthrough Therapy Designation for RRP Treatment
Avenge Bio’s AVB-001 Granted FDA Orphan Drug Designation for Mesothelioma Treatment
According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$6,425 MN in 2020 and expected to reach ~$ 12,346 MN by the end of 2030 (10 years of markets forecasting). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
According to Thelansis, the global Crohn’s disease (CD) market was estimated at ~$6,425 MN in 2020 and expe…
According to Thelansis, the global Chemotherapy-Induced Peripheral Neuropathy (CIPN) in 8 MM countries is estimated to be USD ~2.6 BN in 2020, USD and USD 4.7 BN by the end of 2030 (10 years of markets forecasting). They attribute the high growth to the launches of Opioid analgesics, Alpha-2-delta antagonists, SNRI, Tricyclic antidepressants, analgesics, and Others,
According to Thelansis, the estimated total patient…
EXPLORE MEDIA
OTHER LINKS
REACH US
Sales office
US: +1 (267) 244-6955
Delivery Office
India: +91 (124)-4041731
Head – Business Development and Partnering
Mr. Pankaj Negi has joined Thelansis as Practice Head; Business Development and Partnering, since Jan 2020. A dynamic professional with 12+ years of diverse experience across Pharmaceuticals/ Healthcare/ Life sciences with specialized in sales & marketing and Business Development.
Mr. Pankaj is holding a Master’s degree in “Pharma Management” from the Rajiv Gandhi University of Health Science, Bangalore, India and has expertise in Content Marketing, Content Management systems, Customer Relationship Management, online marketing, advertising, promotion, and Search Engine Optimization. Creating and implementing client-centered, successful campaigns, aimed at improving brand awareness and presence.
Vice President – Delivery, Scientific CI
Mukesh Kumar has joined us as Vice President – Delivery & Innovations, Scientific CI Practice, since August 2019. Prior to joining us, Dr. Mukesh holding a Postdoctoral Fellow with a demonstrated history of working in hard-core research for more than 15 years on both small molecule and biologics within the oncology and neurology segment.
Skilled in Recombinant DNA, Phage Display Technology, Antibodies, ImmunoOncology (K-RAS, Check-Point, Oncolytic), and Immunotherapeutic (RNA andProtein/huMab-based) products, Cancer-stem Cells, Chemoresistance, Real-TimePolymerase Chain Reaction (qPCR), and SDS-PAGE. Strong research professional with a Ph.D. focused on Recombinant Antibody-mediated tumor targeting. Dr.Mukesh has several citations on Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis, Membrane, Fusion Mediated Targeted Cytosolic DrugDelivery Through scFv Engineered Sendai Viral Envelopes, and Drug combination targeting hypoxia-induced chemoresistance and stemness in glioma cells.
Director – Practice Head, Competitive Intelligence, Market Access, and Pricing
Mr. Peeyush Potdar is working at Thelansis as Practice Head; Competitive Intelligence, Market Access, and Pricing Analytics, since Dec 2017. With 12+ years of rich experience in providing business consulting and research support across competitive intelligence, BD&L activities, KOL management, business research, and analytics services, he has been involved in the development of syndicated therapy area specialized reports in Orphan & ultra-orphan indications and conducting market intelligence assignments on different verticals such as Pharmaceuticals, Medical Devices and Health Insurance.
Mr. Peeyush is holding an MBA degree in “Pharma Management” from the National Institute of Pharmaceutical Education & Research (NIPER), Mohali, India and has expertise in scientific research as well as in commercialization and lifecycle management for innovative and mature assets. He has a good competency in building AI/ ML-based analytics platforms for tracking global conferences, social media analytics, and for conducting patient outcomes research.
Director – Global Relationship and Partnering US
Ms. Martina is working with us as Director – Global Relationship and Partnering US, since October 2019. Prior to joining us, Ms. Martina holding a Master’s Degree in Public Health from Boston University School of Public Health with more than 8 years of experience in B2B and B2C sales. Highly motivated and accomplished sales and marketing professional with a proven history of success in creating the road map and driving business development globally.
Part of US Leadership team and heading Business Development for Thelansis Knowledge Partner for both US and EU Region. Business Development opportunity identification, Engaging with the client and providing them with innovative business solutions.
Director – Global Relationship and Partnering EU
